CureVac AG : Curevac is a private German company with mRNA platform, diversified pipeline, and three lead programs in ph1: CV8102 (various cancer indications), CV9202 (NSCLC) and CV7202 (Rabies). Last financing round done at over $1bn. Other companies in the space: MRNA, TBIO, BNTX.
• Lead Programs:
o CV8102 (melanoma, adenoidcystic carcinoma, sq cell cancer of skin and H&N) in Ph 1
 Ph1 date readout expected mid-2021
 Ph2 trial initiation 2H 2021
o CV9202 (NSCLC) in Ph 1
o CV7202 (Rabies) in Ph 1
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Autoimmune, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Platform Technology
Website:
Profiles:
Address:
Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020